US FDA panel calls for additional CV studies for weight-loss drugs
This article was originally published in Scrip
Executive Summary
New weight-loss drugs in development could not escape the history of the notorious Fen-Phen (fenfluramine/phentermine/dexfenfluramine), which was banned from the market in 1997, at a 29 March US FDA meeting, where advisers to the agency recommended that makers of anti-obesity medicines be required to conduct additional trials to rule out cardiovascular (CV) risks, even though a product has not demonstrated a signal for that type of harm.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.